Pharmacodynamics of FLC generic products compared with the innovator against <i>C</i>. <i>albicans</i> GRP-0144.

<p>Data from three independent experiments were combined and analyzed by CFA. The innovator (Diflucan) and Claris products were included in all three experiments (54 animals per product), Fresenius in two (36 animals) and Vitalis in one (18 animals). A single curve (solid black line) described the data better than individual ones, indicating that the generics were therapeutically equivalent to the innovator. The horizontal dotted line indicates the fungal load at the beginning of therapy (0 h).</p

Pharmacodynamics of FLC generic products compared with the innovator against <i>C</i>. <i>albicans</i> CIB-19177.

<p>Data from two independent experiments were combined and analyzed by CFA. The innovator (Diflucan) was included in both experiments (42 animals), and Claris, Fresenius and Vitalis in one (21 animals per product). A single curve (solid black line) described the data better than individual ones, indicating that the generics were therapeutically equivalent to the innovator. The horizontal dotted line indicates the fungal load at the beginning of therapy (0 h).</p

Fluconazole products included in the study.

<p>* The price was estimated with the exchange rate at the time of the study (2012).</p><p>Fluconazole products included in the study.</p